

# USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2022 TO 9/30/2023

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
<b>UNIT: Mitchell Cancer Institute</b>							
<b>USA Health Clinical Trials</b>							
Abdalla,	Ahmed	NRG	NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ONEVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)	A23-0192-001	New	9/30/2023	\$0
Alkharabsh	Omar	SGI	A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral	A20-0089-003	Continuation	9/30/2023	\$77,493
Alkharabsh	Omar	LOXOI	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus	A22-0041-002	Continuation	9/30/2023	\$78,134
Alkharabsh	Omar	BMSI	A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing CC-92489 (BMS-986348), Carfilzomib, and Dexamethasone	A23-0085-001	New	5/3/2023	\$35,032
Butler,	Thomas	XIAPHAR	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus	A23-0193-001	New	9/25/2023	\$0
Cohen,	Michael	BIP	Cluster-randomized clinical trial to test the effectiveness of an innovative, clinic-level implementation strategy to improve the	A20-0072-004	Continuation	9/30/2023	\$1,825
Dyess,	Donna	GNTC	B59	A18-0198-006	Continuation	9/30/2023	\$40,095
Eyal,	Fabien	RDOI	Reference Range and Clinical Performance Evaluation of Elecsys IL-6 Assay in Neonatal Sepsis (US); Collection Study.	A23-0093-001	New	4/26/2023	\$0
Gremse,	David	TPC	A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole	A22-0236-001	New	6/2/2023	\$0
Gremse,	David	FPI	A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic	A23-0108-001	New	6/22/2023	\$0
Howard,	John	NIH	A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-Risk Melanoma	A19-0252-004	Continuation	9/30/2023	\$8,550
Howard,	John	MERCK	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following	A21-0219-003	Continuation	9/30/2023	\$47,471
Howard,	John	CARIS	The Caris Biorepository Research Protocol	A21-0237-002	Continuation	9/30/2023	\$5,362

# USA HEALTH CLINICAL TRIALS ACTIVITY

**10/1/2022 TO 9/30/2023**

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Howard,	John	NIH	S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide	A23-0095-001	New	5/12/2023	\$0
Howard,	John	NIH	S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide	A23-0095-002	Continuation	9/30/2023	\$10,800
Imran,	Hamayun	NIH	CHOP workload Intensity U10CA180886 NCTN Operations grant.	A21-0184-004	Continuation	9/30/2023	\$11,000
Imran,	Hamayun	NIH	PER CASE REIMBURSEMENT NCTN Operations Grant U10CA180886	A21-0185-003	Continuation	9/30/2023	\$36,876
Imran,	Hamayun	PHI	CHILDREN'S ONCOLOGY GROUP PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955Per Case Reimbursement (PCR)	A21-0228-002	Continuation	9/30/2023	\$8,720
Imran,	Hamayun	PHI	A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the	A22-0093-002	Continuation	9/30/2023	\$6,000
Imran,	Hamayun	AMAZON	Amazon supplemental Payments	A22-0200-002	Continuation	9/30/2023	\$10,000
Jones,	Nathaniel	MERCK	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without	A21-0119-003	Continuation	9/30/2023	\$139,475
Khushman,	Moh'D	ABVI	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-	A20-0061-004	Continuation	9/30/2023	\$1,285
Khushman,	Moh'D	NAT	BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer	A21-0065-003	Continuation	9/30/2023	\$20,522
Pai,	Sachin	INC	A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects	A19-0035-005	Continuation	9/30/2023	\$29,504
Pai,	Sachin	NIH	LUNGMAP, A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-	A19-0247-004	Continuation	3/10/2023	\$0
Pai,	Sachin	NIH	LUNGMAP, A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-	A19-0247-005	Continuation	9/30/2023	\$958
Pai,	Sachin	MERCK	MCI Merck 5890-001 Ph 1 Solid Tumor	A20-0033-004	Continuation	9/30/2023	\$32,640

## USA HEALTH CLINICAL TRIALS ACTIVITY

**10/1/2022 TO 9/30/2023**

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Persing,	Brian	NIH	A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer	A21-0037-002	Continuation	9/30/2023	\$2,900
Proddaturv	Pranitha	SGI	SGNTUC-016 HER2+	A20-0107-004	Continuation	9/30/2023	\$21,612
Proddaturv	Pranitha	BMSI	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant	A20-0124-004	Continuation	9/30/2023	\$24,332
Proddaturv	Pranitha	ASTZ	SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus	A21-0233-002	Continuation	9/30/2023	\$4,060
Proddaturv	Pranitha	GNTC	A PHASE II, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, CONTROLLED STUDY OF FRO7247669 PLUS PLATINUM-	A23-0189-001	New	9/30/2023	\$0
Rocconi,	Rodney	CLSC	Celsion GEN 1 Ovarian	A18-0146-005	Continuation	9/30/2023	\$15,006
Rocconi,	Rodney	MERCK	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of	A20-0030-004	Continuation	3/10/2023	\$5,253
Rocconi,	Rodney	EXE	CABO - A phase II Study of Cabozantinib for Recurrent, or Persistent Cervical Cancer	A20-0108-002	Continuation	9/30/2023	\$2,250
Saleemi,	Adeel	NIH	ARCADIA Clinical Trial through the NIH StrokeNet	A20-0066-004	Continuation	9/30/2023	\$11,834
Scalici,	Jennifer	NIH	A Phase III study comparing single agent Olaparib or the combination of Cediranib and Olaparib to Standard platinum- based	A16-0057-002	Continuation	3/10/2023	\$0
Scalici,	Jennifer	GOG	Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer	A21-0117-002	Continuation	9/30/2023	\$71,424
Scalici,	Jennifer	GOG	A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH	A23-0061-001	New	3/15/2023	\$54,599
Scalici,	Jennifer	GENE	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec follow ed by	A23-0109-001	New	6/22/2023	\$0
Scalici,	Jennifer	KGB	Platinum-doublet Chemotherapy and A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian	A23-0174-001	New	9/26/2023	\$0

# USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2022 TO 9/30/2023

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Sugg,	Rebecca	NIH	Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE) Study	A20-0175-002	Continuation	9/30/2023	\$3,178
<b>TOTAL FOR DEPARTMENT: USA Health Clinical Trials</b>							<b>\$818,192</b>